drugset
drugset / Trial / NCT04322890

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

NCT04322890 ↗

Phase 2 Recruiting 6000 enrolled Hunan Province Tumor Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Timeline

Start
2020-04-16
Primary completion
2026-12-24
Completion
2027-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Alectinib Small molecule 600 mg Oral
Subject Cisplatin Other / unclassified 500 mg Intravenous
Subject Crizotinib Small molecule 250 mg Oral
Subject Lorlatinib Small molecule 100 mg Oral
Subject Osimertinib Small molecule 80 mg Oral
Subject Pemetrexed Small molecule 500 mg Intravenous
Subject Pralsetinib Small molecule 500 mg Intravenous
Subject Savolitinib Small molecule 300 mg Oral

Indications

non-small cell lung carcinoma